Ethambutol 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
Standard duration for uncomplicated disease is 6 months total, though it is extended if high risk of relapse (see below)
Treatment for multidrug-resistant tuberculosis is discussed separately
Special populations
For the elderly, or those at elevated risk of hepatotoxicity: can do induction phase withoutpyrazinamide and extend continuation phase to 7 months (from 4)
For pregnant women: can consider dropping pyrazinamide and extending the course by 3 months, but if there is severe disease then likely should follow standard treatment
For high risk of relapse, including extensive or cavitary disease in the first 2 months of treatment, culture-positivity after 2 months of treatment, or cavitary disease on CXR at end of treatment: the consolidation phase should be extended by 3 months (to 9 months total treatment)
Recommend a fluoroquinolone, ethambutol, and amikacin for 2 months followed by fluroquinolone and ethambutol for 18 months
Can consider adding rifampin if they are monitored closely
Infection control
Airborne precautions until:
Treated for at least 2 weeks and symptoms are clearly improving
3x negative sputum smears
They can be discharged home when clinical improvement, drug-resistant TB is not suspected and there is no contraindication for home isolation
References
^Chandrasekaran Padmapriydarsini, Megha Mamulwar, Anant Mohan, Prema Shanmugam, N S Gomathy, Aarti Mane, Urvashi B Singh, Nathella Pavankumar, Abhijeet Kadam, Hemanth Kumar, Chandra Suresh, Devaraju Reddy, Poornaganga Devi, P M Ramesh, Lakshmanan Sekar, Shaheed Jawahar, R K Shandil, Manjula Singh, Jaykumar Menon, Randeep Guleria. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis. Clinical Infectious Diseases. 2021;75(3):425-434. doi:10.1093/cid/ciab964.